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Enzymatic and non-enzymatic post-translational
modiﬁcations linking diabetes and heart
disease
Diabetes-related morbidity and mortality
is evident in the increased prevalence of
cardiovascular diseases and the high-risk
of heart failure. Diabetic cardiomyopathy
is a well-known complication of diabetes,
and is deﬁned as a ventricular dysfunc-
tion independent of coronary heart
diseases and hypertension. The Framing-
ham study ﬁrmly established an epidemi-
ological link between diabetes and heart
failure1. Diabetes causes metabolic distur-
bances, cardiac ﬁbrosis, endothelial and
vascular smooth muscle cell dysfunctions,
altered contractile performance, and
arrhythmia. The underlying mechanisms
of the adverse effects of diabetes on the
heart remain poorly understood. How-
ever, it is certain that diabetic heart dis-
ease is a consequence of multiple factors
including uncontrolled hyperglycemia,
insulin resistance and dyslipidemia.
Chronic hyperglycemia causes glucose
toxicity, which mediates the detrimental
effects of diabetes through the activation
of a number of pathways, such as the
polyol pathway, oxidative stress, mito-
chondrial dysfunction, activation of pro-
tein kinases, hexosamine biosynthesis
pathway and non-enzymatic glycation
reaction. The hexosamine biosynthesis
pathway generates uridine diphosphate-
N-acetylglucosamine (UDP-GlcNAc),
which is an activated precursor for both
N-linked and O-linked glycosylation of
proteins, and the substrate for b-O-linked
GlcNAc (O-GlcNAc) modiﬁcation of pro-
teins (Figure 1). Recently, O-GlcNAc
covalent modiﬁcation of cardiac proteins
has received considerable attention as a
key factor in diabetic cardiac pathology2,3.
In contrast to non-enzymatic glycation
reactions, O-GlcNAc glycosylation is a
reversible and labile post-translational
modiﬁcation.
After entering a cell, glucose is phos-
phorylated to glucose-6-phosphate (Fig-
ure 1). It is further metabolized during
glycolysis to fructose-6-phosphate, which
leads to accessory pathways of glucose
metabolism; one such pathway is the
hexosamine biosynthesis pathway. Under
normal physiological conditions, approxi-
mately 5% of intracellular glucose enters
the hexosamine biosynthesis pathway;
however, its ﬂux is upregulated in dia-
betic cardiomyocytes4. The rate-limiting
enzyme glutamine, fructose-6-phosphate
aminotransferase (GFAT), converts fruc-
tose-6-phosphate to glucosamine-6-phos-
phate, which is then converted into
UDP-GlcNAc and transferred onto target
proteins by O-GlcNAc transferase
(OGT). The enzyme, O-GlcNAcase, cata-
lyzes the removal of the O-GlcNAc
adduct from O-GlcNAcylated proteins
(Figure 1)2. O-GlcNAcylation is reported
to be involved in a number of cellular
processes including signal transduction,
protein–protein interactions, translation,





































Figure 1 | Hexosamine biosynthesis pathway. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; GFAT, glutamine:fructose-6-phosphate amidotransferase; OGT, O-linked
N-acetylglucosamine (GlcNAc) transferase; O-GlcNAcase, O-GlcNAc-selective
beta-N-acetylglucosaminidase; UDP-GlcNAc, uridine diphosphate-N-acetylglucosamine.
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alteration4. Recently, O-GlcNAcylation
has been shown in the regulation of car-
diomyocyte excitation-contraction cou-
pling by inﬂuencing intracellular Ca2+
homeostasis5. The multifunctional Ca2+
and calmodulin-dependent protein
kinase II (CaMKII) is a serine-threonine
kinase that is activated by an increase in
cellular Ca2+. The disruption of normal
intracellular Ca2+ homeostasis is the
event mainly responsible for initiating
and perpetuating myocardial dysfunction,
electrical instability, and arrhythmia. The
CaMKII regulates Ca2+ homeostasis pro-
teins in the myocardium. Recently, it has
been reported that O-GlcNAc modiﬁca-
tion of CaMKII leads to cardiac arrhyth-
mias associated with diabetes, which are
linked to heart failure and sudden car-
diac death2. CaMKII fusion with O-Glc-
NAc leads to chronic overactivation of
CaMKII, triggering arrhythmias, and
inhibition of O-GlcNAcylation of CaM-
KII prevented the occurrence of arrhyth-
mias2. In addition to direct O-GlcNAc
modiﬁcation of proteins involved in exci-
tation-contraction coupling, nuclear
O-GlcNAcylation of transcription factors,
histones and ribonucleic acid (RNA)
polymerase II has been known to alter
gene transcription, resulting in cardiac
deterioration in patients with diabetes3.
Compared with the dynamic and
enzymatic regulation of O-GlcNAcyla-
tion, non-enzymatic glycation-modiﬁca-
tion is generally irreversible and
obstructive. Both extracellular and intra-
cellular formation of advanced glycation
end-products (AGE) occurs in proteins
such as collagen and other matrix com-
ponents, and in cardiomyocyte intracellu-
lar proteins. The involvement of AGE-
modiﬁcation in excitation-contraction
coupling has been described in type 1
diabetic rat myocardium, including the
sarcoplasmic reticulum Ca2+ adenosine
triphosphatase (ATPase; SERCA2) and
ryanodine receptor 2 (RYR2), a Ca2+
release channel6. Remodeling and degra-
dation of the extracellular matrix is also
affected in diabetes as a result of reduced
expression of matrix metalloproteinases
and consequent lower collagen turnover7.
Binding of AGE to the receptor for AGE
(RAGE) on ﬁbroblasts stimulates collagen
production, further compromising ven-
tricular compliance8. We also reported
that AGE and RAGE impaired Ca2+
homeostasis in diabetic mouse myocytes;
thus, accounting for the abnormal con-
tractile and relaxation functions9.
Diabetic cardiomyopathy involves vari-
ous complex functional and structural
abnormalities. Recent ﬁndings highlight
the dynamic O-GlcNAcylation and irre-
versible glycation of fundamental cardio-
myocyte proteins in the context of
diabetes. This can potentially be used to
study enzymatic and non-enzymatic
post-translational modiﬁcations associated
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